Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis

• DOI: 10.3389/fonc.2022.1003426
• Publication Date: 2022-11-22T07:25:00Z
• Authors: He-nan Qin; Zhen Ning; Rui Sun; Chen-xing Jin; Xin Guo; A-man Wang; Ji-wei Liu
• Keywords: Lenvatinib; Second line treatment

The purpose of this study is to determine the efficacy and safety lenvatinib as second-line therapy in Chinese patients with unresectable hepatocellular carcinoma (HCC). We performed a retrospective analysis HCC who received treatment at three institutions from November 2018 February 2022. Demographic clinicopathologic characteristics, data on regimens were obtained medical records. Tumor response was evaluated every 4-6 weeks by modified Response Evaluation Criteria Solid Tumors (mRECIST). In total, 50 enrolled study. objective rate (ORR) 18.0% disease control (DCR) 74.0%, respectively. duration (DoR) 6.0 months. median progression-free survival (PFS) overall (OS) 5.0 8.5 months, Patients ICIs combined anti-angiogenic inhibitors first-line therapy, achieving CR/PR PFS≥6months had higher DCR. Univariate multivariate showed that AFP (ng/ml)<400, absence extrahepatic metastasis, Child-Pugh A, tumor number<3, independent factors favorable PFS. significantly associated longer OS. Multivariate prognostic majority AEs grade 1-2, reversible. Grade 3/4 occurred 12 (24.0%) mostly connected hand-foot skin reactions (10.0%), 10 dose reductions. Two toxicity-related interruptions attributed 3 reaction, 4 proteinuria, This confirms after progression sorafenib or inhibitors.